{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:51:59Z","timestamp":1785887519508,"version":"3.56.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Circulating tumor cells (CTCs) hold promise for use in personalized medicine for hepatocellular carcinoma (HCC). Their abundance and molecular characteristics may predict disease prognosis and could be used to monitor responses to treatment in specific types of cancers. The present case report described a 52-year-old woman with metastatic HCC with an extensive treatment history. The patient\u2019s CTCs demonstrated EGFR surface mutations, specifically, an EGFR exon 19 deletion and an L858R mutation. Based on this finding, the patient\u2019s metastatic lung lesions were treated with an EGFR tyrosine kinase inhibitor-based regimen, which achieved a partial response that was confirmed using the Response Evaluation Criteria in Solid Tumors (version 1.1). Notably, the patient benefited from this therapy regimen for a period of 14 months. The progression of precision medicine in HCC has been hampered by difficulties in identifying cancer driver genes and the limited utilization of histological diagnosis. The findings of the present study suggest that molecular analysis of CTCs may have the potential to guide personalized HCC treatment strategies in the future.<\/jats:p>","DOI":"10.3389\/fonc.2025.1608604","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:41:36Z","timestamp":1758087696000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular profiling of circulating tumor cells guides effective EGFR inhibitor treatment in advanced hepatocellular carcinoma: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Wei","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan\u2010Mou","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"Bclc strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.04.001","article-title":"Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of hcc","volume":"33","author":"Stigliano","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41571-023-00781-y","article-title":"Circulating tumour cells for early detection of clinically relevant cancer","volume":"20","author":"Lawrence","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31165","article-title":"Detection of circulating tumor cells and their implications as A biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma","volume":"73","author":"Ahn","year":"2021","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"111298","DOI":"10.1016\/j.celrep.2022.111298","article-title":"Circulating tumor cell-blood cell crosstalk: biology and clinical relevance","volume":"40","author":"Pereira-Veiga","year":"2022","journal-title":"Cell Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6104","article-title":"Perk\/pakt Phenotyping In Circulating Tumor Cells As A Biomarker For Sorafenib Efficacy In patients with advanced hepatocellular carcinoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2018.02.004","article-title":"Evaluation of hepatocellular carcinoma circulating tumor cells expressing programmed death-ligand 1","volume":"20","author":"Winograd","year":"2018","journal-title":"Hpb (Oxford)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2174\/0113892029308243240709073945","article-title":"Integrative bioinformatics analysis for targeting hub genes in hepatocellular carcinoma treatment","volume":"26","author":"Gudivada","year":"2025","journal-title":"Curr Genomics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2174\/0113892029313473240919105819","article-title":"Cdt1 is A potential therapeutic target for the progression of nafld to hcc and the exacerbation of cancer","volume":"26","author":"He","year":"2025","journal-title":"Curr Genomics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3892\/or.2016.5050","article-title":"Circulating tumour cells as biomarkers for evaluating cryosurgery on unresectab le hepatocellular carcinoma","volume":"36","author":"Shi","year":"2016","journal-title":"Oncol Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3390\/cancers16061213","article-title":"Advancements in circulating tumor cell research: bridging biology and clinical applications","volume":"16","author":"Salu","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised recist guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.12.008","article-title":"Novel egfr mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858r mutation in exon 21 by immunohistochemistry","volume":"83","author":"Seo","year":"2014","journal-title":"Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0129","article-title":"Immunohistochemical detection of egfr mutation using mutation-specific antibodies in lung cancer","volume":"16","author":"Kitamura","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.lungcan.2011.02.002","article-title":"Identification of non-small-cell lung cancer with activating egfr mutations in Malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858r mutation by immunocytochemistry","volume":"74","author":"Kawahara","year":"2011","journal-title":"Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023303","article-title":"Including total egfr staining in scoring improves egfr mutations detection by mutation-specific antibodies and egfr tkis response prediction","volume":"6","author":"Wu","year":"2011","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1309\/WF10QAAED3PP93BH","article-title":"Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma","volume":"129","author":"Buckley","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27604","article-title":"Egfr activation is A potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib","volume":"131","author":"Ezzoukhry","year":"2012","journal-title":"Int J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26898","article-title":"Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma","volume":"59","author":"Fuchs","year":"2014","journal-title":"Hepatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41392-024-02085-8","article-title":"Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: A prospective, single-arm exploratory trial","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduction Target Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.7746","article-title":"Search: A phase iii, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma","volume":"33","author":"Zhu","year":"2015","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","article-title":"Genetic landscape and biomarkers of hepatocellular carcinoma","volume":"149","author":"Zucman-Rossi","year":"2015","journal-title":"Gastroenterology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgac099","article-title":"Dissecting intratumor heterogeneity in hcc: new research strategies and clinical implications","volume":"43","author":"Behrens","year":"2022","journal-title":"Carcinogenesis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.165","article-title":"The significance of intertumor and intratumor heterogeneity in liver cancer","volume":"50","author":"Liu","year":"2018","journal-title":"Exp Mol Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","article-title":"Hepatocellular carcinoma: signaling pathways and therapeutic advances","volume":"10","author":"Zheng","year":"2025","journal-title":"Signal Transduction Target Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1097277","article-title":"Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1038\/s41467-021-24386-0","article-title":"Dissecting spatial heterogeneity and the immune-evasion mechanism of ctcs by single-cell rna-seq in hepatocellular carcinoma","volume":"12","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"171845","DOI":"10.1155\/2015\/171845","article-title":"Missense mutations in exons 18\u201324 of egfr in hepatocellular carcinoma tissues","volume":"2015","author":"Panvichian","year":"2015","journal-title":"BioMed Res Int"},{"key":"B31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13578-020-00407-1","article-title":"Hcc-derived egfr mutants are functioning, egf-dependent, and erlotinib-resistant","volume":"10","author":"Sueangoen","year":"2020","journal-title":"Cell Biosci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03741-7","article-title":"Egfr activation limits the response of liver cancer to lenvatinib","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"8007","DOI":"10.1038\/s41598-022-12076-w","article-title":"Egfr inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells","volume":"12","author":"He","year":"2022","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-4140","article-title":"Inhibition of egfr overcomes acquired lenvatinib resistance driven by stat3-abcb1 signaling in hepatocellular carcinoma","volume":"82","author":"Hu","year":"2022","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2459","article-title":"Circulating tumor cells undergoing emt provide A metric for diagnosis and prognosis of patients with hepatocellular carcinoma","volume":"78","author":"Qi","year":"2018","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0498","article-title":"Isolation of circulating tumor cells in patients with hepatocellular carcinoma using A novel cell separation strategy","volume":"17","author":"Xu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41698-020-0123-0","article-title":"Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells","volume":"4","author":"Court","year":"2020","journal-title":"NPJ Precis. Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2019.09.13","article-title":"Limited bias effect of intratumoral heterogeneity on genetic profiling of hepatocellular carcinoma","volume":"11","author":"Huang","year":"2020","journal-title":"J Gastrointest. Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","article-title":"Molecular pathogenesis and systemic therapies for hepatocellular carcinoma","volume":"3","author":"Llovet","year":"2022","journal-title":"Nat Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1608604\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:41:37Z","timestamp":1758087697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1608604\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":39,"alternative-id":["10.3389\/fonc.2025.1608604"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1608604","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"article-number":"1608604"}}